Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6844975 | 0.91 | GAA (0.40) | GAAIDH1MEN1KMT2AHIF1A | |
| SCHEMBL577916 | 0.90 | GAA (0.39) | GAAIDH1MEN1KMT2AHIF1A | |
| SCHEMBL577706 | 0.83 | GAA (0.40) | GAAIDH1MEN1KMT2AHIF1A | |
| SCHEMBL578111 | 0.76 | IDH1 (0.46) | IDH1LMNA | |
| SCHEMBL29660508 | 0.75 | IDH1 (0.38) | IDH1MEN1KMT2A | |
| SCHEMBL577625 | 0.75 | IDH1 (0.45) | IDH1HIF1ALMNA | |
| SCHEMBL14706482 | 0.74 | PPARD (0.33) | GAAIDH1MEN1KMT2APPARD | |
| SCHEMBL14706467 | 0.73 | BLM (0.47) | IDH1MEN1KMT2A | |
| SCHEMBL577917 | 0.73 | IDH1 (0.37) | GAAIDH1MEN1KMT2APPARD | |
| SCHEMBL578255 | 0.73 | KMT2A (0.41) | MEN1KMT2ASMN1; SMN2PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353100-B2 | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353100-B2 | Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2461811-B1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX PHARMACEUTICALS LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-9284307-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS LLC (US) | 2016-03-15 | — | — | US | disclosed |
| US-8993595-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993595-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20130224147-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130224147-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8377962-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8377962-B2 | Macrocyclic serine protease inhibitors | IDENIX PHARMACEUTICALS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120207703-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING HCV INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20120207703-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING HCV INFECTIONS | IDENIX PHARMACEUTICALS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20110129443-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-20110129443-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| WO-2011017389-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| WO-2010118078-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120207703-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING HCV INFECTIONS | PRSS1, SERPINB1, SPINT2 | GAA 336/4885IDH1 1989/4885MEN1 3349/4885 |
| US-20110129443-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | GAA 388/4885IDH1 1513/4885MEN1 3502/4885 |
| US-20130224147-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | GAA 388/4885IDH1 1513/4885MEN1 3502/4885 |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | GAA 388/4885IDH1 1513/4885MEN1 3502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.